The design and application of label free detection in droplet interface bilayers for drug discovery relevant permeation studies
Robert Strutt a b, Felix Sheffield a b, John Harling c, Robert Law a b, Nicholas Brooks a b, Laura Barter a b, Anthony Flemming d, Oscar Ces a b
a Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, Shepherd’s Bush, London, W12 0BZ, UK
b Institute of Chemical Biology, Imperial College London, Molecular Sciences Research Hub, Shepherd’s Bush, London, United Kingdom
c Medicinal Chemistry, GlaxoSmithKline, Gunnels Wood Road, Stevenage, United Kingdom
d Syngenta, Jealott’s Hill International Research Centre, Bracknell, Berkshire, RG42 6EY, UK, Jealotts Hill Research Station, Jealott's Hill, Warfield, Bracknell RG42 6EY, Reino Unido, Warfield, United Kingdom
Proceedings of Emerging Investigators in Microfluidics Conference (EIMC)
Online, Spain, 2021 July 20th - October 6th
Organizers: Adrian Nightingale, Darius Rackus and Claire Stanley
Oral, Robert Strutt, presentation 004
DOI: https://doi.org/10.29363/nanoge.eimc.2021.004
Publication date: 5th July 2021

Biologically active chemistry is mostly concerned with the design of compounds able to translocate biological membranes; complex organelles of interwoven lipids, sugars and proteins. Historically, much work has focused on simple diffusion across the lipid matrix as a major transport route. Current in vitro assays to delineate a small molecules structural dependency on different transport routes have been limited, where typically the model interface is oversimplified. Droplet interface bilayers (DIBs) are formed at the contact of two lipid monolayer coated water in oil droplets and have shown vast potential within biomimetic synthetic biology. DIB technology is highly applicable within microfluidics and bespoke chip design, in particular as a chassis for the study of permeant translocation across biomimetic membranes. Up till now, permeation studies within DIBs have mostly utilised fluorescent microscopy, thus limiting the application of DIB technology in divergent physicochemical space typical of small molecule drug discovery. Here, we address this technological bottleneck by presenting a novel, label free approach enabled by custom chip design principles. Our method is highly implementable in multiple applications and can perform in situ measurement with a data interval as low as 0.02 s. Our platform has enabled us to undertake structure - function relationship studies across compositionally varied bilayers unlocking the complementarity of DIB technology to current widely used assays.

© FUNDACIO DE LA COMUNITAT VALENCIANA SCITO
We use our own and third party cookies for analysing and measuring usage of our website to improve our services. If you continue browsing, we consider accepting its use. You can check our Cookies Policy in which you will also find how to configure your web browser for the use of cookies. More info